Johnson & Johnson has paused all U.S. Varipulse cases as it investigates four reported neurovascular events.
In a pivotal study, three of 277 patients (1.1%) had cerebrovascular events (two strokes and one transient ischemic attack).
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,